Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas D James

Showing results (1-10 of 197) with videos related to

Pageof 20
Sort By:
European Urology Focus|February 27, 2019
Oligometastatic Prostate Cancer Should Be Studied and Treated Differently to High-volume Disease. Con: The Underlying Biology is the Same, So They Should Not Be Treated DifferentlyNicholas D James
BJU International|September 7, 2018
Prognostic and predictive models in hormone-sensitive prostate cancerNicholas D James
Current Opinion in Urology|March 7, 2022
The role of radiotherapy in oligometastatic hormone-sensitive prostate cancerHoda Abdel-Aty, Nicholas D James
Expert Review of Anticancer Therapy|December 31, 2002
Organ preservation strategies in bladder cancerSyed A Hussain, Nicholas D James
Oncology (Williston Park, N.Y.)|October 21, 2011
Bladder cancer: time for a rethink?Richard T Bryan, Nicholas D James
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 30, 2013
A multidisciplinary approach in muscle-invasive disease: novel chemotherapy combinations and targets in chemoradiationNicholas D James, Syed A Hussain
European Urology Focus|November 4, 2023
How to Compose Platform TrialsNoel W Clarke, Nicholas D James
Seminars in Radiation Oncology|January 22, 2005
Molecular markers in bladder cancerSyed A Hussain, Nicholas D James
The Lancet. Oncology|August 7, 2003
The systemic treatment of advanced and metastatic bladder cancerSyed A Hussain, Nicholas D James
Urologic Oncology|June 11, 2015
Shifting paradigms in the estimation of survival for castration-resistant prostate cancer: A tertiary academic center experienceMehran Afshar, Felicity Evison, Nicholas D James, et al.
Pageof 20

Showing results (1-10 of 197) with videos related to

Sort By:
Pageof 20
European Urology Focus|February 27, 2019
Oligometastatic Prostate Cancer Should Be Studied and Treated Differently to High-volume Disease. Con: The Underlying Biology is the Same, So They Should Not Be Treated DifferentlyNicholas D James
BJU International|September 7, 2018
Prognostic and predictive models in hormone-sensitive prostate cancerNicholas D James
Current Opinion in Urology|March 7, 2022
The role of radiotherapy in oligometastatic hormone-sensitive prostate cancerHoda Abdel-Aty, Nicholas D James
Expert Review of Anticancer Therapy|December 31, 2002
Organ preservation strategies in bladder cancerSyed A Hussain, Nicholas D James
Oncology (Williston Park, N.Y.)|October 21, 2011
Bladder cancer: time for a rethink?Richard T Bryan, Nicholas D James
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 30, 2013
A multidisciplinary approach in muscle-invasive disease: novel chemotherapy combinations and targets in chemoradiationNicholas D James, Syed A Hussain
European Urology Focus|November 4, 2023
How to Compose Platform TrialsNoel W Clarke, Nicholas D James
Seminars in Radiation Oncology|January 22, 2005
Molecular markers in bladder cancerSyed A Hussain, Nicholas D James
The Lancet. Oncology|August 7, 2003
The systemic treatment of advanced and metastatic bladder cancerSyed A Hussain, Nicholas D James
Urologic Oncology|June 11, 2015
Shifting paradigms in the estimation of survival for castration-resistant prostate cancer: A tertiary academic center experienceMehran Afshar, Felicity Evison, Nicholas D James, et al.
Pageof 20